By Angela LaRue President & CEO LaRue Company
The last few years have been industry-changing for breast implant manufacturers. The FDA has been bombarded with complaints from women who say that breast implants make them sick. Many women are concerned that their breast implants may be leaking silicone into their bodies. Silicone can migrate to a patient’s lungs, liver, or other organs where surgeons cannot retrieve it. As a result, some studies have been conducted regarding the health consequences of breast implants and the best practices for treating ruptured breast implants. Still, more evidence is needed to provide a consensus on how breast implants affect a patient’s health. Initial studies offer proof that removing breast implants in a no-touch method should be the standard of care that ensures the most silicone removal with the best results for a patient’s health. As a response in late 2021, the FDA placed a black box warning on breast implants, added new breast implants’ sale restrictions, and called for post-approval surveillance studies by implant manufacturers.
One out of every four women has breast implants, and the rupture leaking rate of breast implants is as high as 43.9%. This is very concerning for women all over the world. A LaRue Company has made it its mission to provide surgeons with a safe, no-touch ruptured breast implant removal method and a way to offer uncontaminated specimens to help further breast implant studies. Our twice-patented LaRue Surgical Evacuator provides surgeons with the easiest, fasted ruptured breast implant removal method and provides patients with the peace of mind that the silicone has been removed safely and effectively. At A LaRue Company, Less Mess=Less Stress.
By Christina Drake Founder and CEO of Kismet Technologies
The United States spends $14B annually on disinfectants and infection control technologies, approximately 35% of the $40B spent globally, yet more than 1 in 30 patients will still get a healthcare-acquired infection (HAI). US hospitals have a financial impact of $40B each year in dealing with HAIs. Many HAIs are caused by the most severe antibiotic-resistant bacteria and can lead to sepsis or death. Approximately 11% of US patients with HAIs died in 2015. These HAIs include severe illness-causing pathogens such as MRSA and C. difficile. Infections spread when one of these pathogens is spread in a healthcare setting. This can be from a healthcare worker’s hand or commonly touched surfaces (by patient or healthcare worker) such as bed rails, computer keyboards, patient curtains, toilets and sinks. Bacteria and viruses can often survive for months on surfaces and some bacteria can protect themselves for longer survivability through production of biofilms.
Current solutions (wet disinfectants and UV lights) do not adequately address this issue in healthcare settings. Current disinfectants need to stay wet on a surface for minutes to adequately disinfect and do not disinfect beyond initial application. After disinfection, if a person carrying a pathogen interacts with that surface, that bacteria or virus is now deposited and can move through the facility. UV lights cannot be safely used in the presence of people, and suffers from the same downfalls as wet disinfectants in not providing long term protection. Our innovation solves this core problem in hospital infection control needs.
Our award winning and patent pending NanoRAD powered coatings and films provide safe, non-stop virus and bacteria protection for up to 3 months on often contacted surfaces. NanoRAD continually provides 99.9999% reduction in pathogens such as MRSA, S. aureus, P. aeruginosa, C. difficile, norovirus and rhinovirus within 2 hours. NanoRAD provides this broad spectrum of pathogen protection with the gentleness of water, verified through third party toxicity tests. NanoRAD is the solution to the long-standing problem of surface disinfection for infection prevention in critical facilities like hospitals.
ATTEND FIME 2022, The Florida international Medical Expo and MEET THE START-UPS:
Some of the contestants that will compete at FIME 2022’s Innov8 Talks include
- Christina Drake, Chief Executive Officer, Kismet Technologies, US
- Angela LaRue, Chief Executive Officer, A LaRue Company, US
- Julia Kurth, Marketing Manager, CUREosity GmbH, Germany
- Patrik Zander, CEO & Founder, RolloGuard AB, Sweden
- Dr Jannis Fischer, Co-Founder & CEO, Positrigo AG, Switzerland
- Rashid Hameed, Chief Executive Officer, XpertFlow, Pakistan
- Josh Rabinowitz, Co-Founder & CEO, Articulate Labs, US
- Rahman Mohammed, CEO& Co-founder, Vivo Doc, US
- Laurie Silver, Communications Director, Eye Control, Israel
- David Santos, Operations, Scan4myHealth, Portugal
- Ulrich Weigelt, Chief Executive Officer, RobotDreams GmbH, Germany
- Livia Bors, Sales and Marketing, Kinepict Health, Hungary
- Rodrigo Alves, Chief Technology Officer, Doctari, Chile
- Tormod Thomsen, Chief Executive Officer, Picterus, Norway
- Dr Jonathan Rosenblum, Chief Executive Officer, Rithem Life Sciences, US
Join us in the FIME Healthcare Transformation Zone where the winner will be picked on July 29th, by an esteemed panel of judges which will include industry leaders, investors, government officials and entrepreneurs. Register FREE https://fimeshow.info/3vx6Rat to attend the Florida International Medical Expo this July 27-29, 2022, at Miami Beach Convention Center. Complimentary events and conferences, visit with 700+ exhibitors from around the globe. If you cannot make the live event, there are 7-weeks of interactive FIME ONLINE – July 11th through August 29th, 2022. For information Contact: Carol Prokap firstname.lastname@example.org